Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibition in Patients With or at High Risk of Coronary Heart Disease

… current developments in the field is provided. Keywords Hypercholesterolemia , low-density lipoprotein cholesterol , … LDL-C levels, representing an autosomal dominant form of hypercholesterolemia. 2,3 Conversely, individuals with … a 40-70 % reduction in LDL-C in individuals with familial hypercholesterolemia and/or atherosclerotic disease when used …

AHA 2020: Evinacumab Safety and Efficacy in HoFH

… function of ANGPTL3, in patients with homozygous familial hypercholesterolemia (HoFH). Questions: 1. What is the …

Quantitation and Visualization of Vasa Vasorum and Neointimal Development in Three Dimensions—High-resolution Microscopic Computed Tomography Analysis

… takes place early after induction of experimental hypercholesterolemia, suggesting a role for … coronary vasa vasorum neovascularization in experimental hypercholesterolemia, J Clin Invest, 1998;101:1551-6. … epicardial endothelial dysfunction in experimental hypercholesterolemia, Cardiovasc Res, 2001;51:762-6. Crossref …

Dyslipidemia: Current Therapies and Guidelines for Treatment

Grape Extracts and Risk Factors for Cardiovascular Disease

… While the etiology of atherosclerosis is very complicated, hypercholesterolemia, oxidative modification of low density … extracts on some of the risk factors for CVD is examined. Hypercholesterolemia Hypercholesterolemia is a sufficient, but not exclusive, …

Current Evidence and Future Directions of PCSK9 Inhibition

… inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are … Atherosclerotic cardiovascular disease , LDL cholesterol , hypercholesterolemia , proprotein convertase subtilisin/kexin … purposes, provided the original work is cited correctly. Hypercholesterolemia is a central risk factor for the …

Support for Combined Administration of Antihypertensive and Lipid-lowering Agents to Reduce Cardiovascular Events—The Emergence of the Multipill

… hypertension. In the US adult population, about 30% have hypercholesterolemia and 50-75%, depending on age range, share both. In addition, hypertension and hypercholesterolemia frequently coexist with diabetes, …

Support for Combined Administration of Antihypertensive and Lipid-lowering Agents to Reduce Cardiovascular Events - The Emergence of the Multipill

… hypertension. In the US adult population, about 30% have hypercholesterolemia and 50-75%, depending on age range, share both. In addition, hypertension and hypercholesterolemia frequently coexist with diabetes, …

Treating Atherogenic Dyslipidemia in Patients with Type 2 Diabetes—The Case for Using Fenofibrate

… of patients currently on a statin do not have a genetic hypercholesterolemia, and both the National Cholesterol … is mandatory first choice in diabetic patients without hypercholesterolemia. Conclusions Fibrates are safe, … J, "Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia", Arteriosclerosis & Thrombosis …

Treating the Common Dyslipidemia in Patients with Type 2 Diabetes—The Effects of Fenofibrate on Cardiovascular Disease Risk

… by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials, … statins equally reduce risk in subjects with or without hypercholesterolemia; statins may be the first choice in …